Transgene Biotek touches the roof on securing USA patent on oral Insulin technology

09 Jan 2019 Evaluate

Transgene Biotek is locked at upper circuit limit at Rs. 3.88, up by 0.18 points or 4.86% from its previous closing of Rs. 3.70 on the BSE.

The scrip opened at Rs. 3.88 and has touched a high and low of Rs. 3.88 and Rs. 3.88 respectively. So far 24261 shares were traded on the counter.

The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 4.26 on 09-Oct-2018 and a 52 week low of Rs. 1.81 on 06-Jul-2018.

Last one week high and low of the scrip stood at Rs. 3.88 and Rs. 3.23 respectively. The current market cap of the company is Rs. 29.40 crore.

The promoters holding in the company stood at 23.64%, while Non-Institutions held 76.36% stake in the company.

Transgene Biotek has been granted United State of America patent on technology for Oral delivery of Insulin and Insulin analogues.

This patent is a feather in the cap of Transgene Biotek's list of global patents. This intimation of patent being granted by USA will strengthen the company's management to justifiably increase its monetary value of its technology for oral delivery of Insulin and its analogues. With emergence of Insulin analogues across the globe from several large pharma companies, Transgene's oral delivery technology shall provide a new dimension for such molecules to deliver them through a convenient and increased patient compliant oral route.

Transgene Biotek (TBL) is engaged in manufacturing drugs.

Transgene Biotek Share Price

7.07 0.14 (2.02%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Apollo Hospital Ent. 7036.65
Max Healthcare Inst 1006.75
Narayana Hrudayalay 1249.35
Aster DM Healthcare 444.55
Global Health 1115.50
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.